PREEMPTION EXEMPTION: FDA-APPROVED ABORTION DRUGS AFTER DOBBS

被引：0
|
作者：
Huber, Jared C. [1 ]
机构：
[1] Univ Notre Dame, Law Sch, Notre Dame, IN 46556 USA
来源：
NOTRE DAME LAW REVIEW | 2023年 / 98卷 / 05期
关键词：
D O I：
暂无
中图分类号：
D9 [法律]; DF [法律];
学科分类号：
0301 ;
摘要：
引用
收藏
页码：2217 / 2255
页数：39
相关论文
共 50 条
  • [21] Preapproval Promises to Voluntarily Withdraw FDA-Approved Drugs
    Lynch, Holly Fernandez
    Sachs, Rachel E.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 328 (24): : 2392 - 2393
  • [22] Screening of FDA-Approved Drugs for Treatment of Emerging Pathogens
    Sisk, Jeanne M.
    Frieman, Matthew B.
    ACS INFECTIOUS DISEASES, 2015, 1 (09): : 401 - 402
  • [23] An analysis of FDA-approved drugs for inflammation and autoimmune diseases
    Kinch, Michael S.
    Merkel, Janie
    DRUG DISCOVERY TODAY, 2015, 20 (08) : 920 - 923
  • [24] RNA as an off-target for FDA-approved drugs
    Christopher R. Fullenkamp
    John S. Schneekloth
    Nature Chemistry, 2023, 15 : 1329 - 1331
  • [25] An analysis of FDA-approved drugs for infectious disease: HIV/AIDS drugs
    Kinch, Michael S.
    Patridge, Eric
    DRUG DISCOVERY TODAY, 2014, 19 (10) : 1510 - 1513
  • [26] FDA-APPROVED INDICATIONS
    ANDERSON, DA
    AMERICAN JOURNAL OF HOSPITAL PHARMACY, 1984, 41 (11): : 2328 - 2328
  • [27] Evaluating physiochemical properties of FDA-approved orally administered drugs
    Reese, Tanner C.
    Devineni, Anvita
    Smith, Tristan
    Lalami, Ismail
    Ahn, Jung-Mo
    Raj, Ganesh V.
    EXPERT OPINION ON DRUG DISCOVERY, 2024, 19 (02) : 225 - 238
  • [28] FDA-Approved Anti-Obesity Drugs in the United States
    Daneschvar, Homayoun L.
    Aronson, Mark D.
    Smetana, Gerald W.
    AMERICAN JOURNAL OF MEDICINE, 2016, 129 (08): : 879.e1 - 879.e6
  • [29] Possible FDA-approved drugs to treat Ebola virus infection
    Shu Yuan
    Infectious Diseases of Poverty, 4
  • [30] Pharmacological Profile of FDA-Approved Orphan Drugs in the Year 2022
    Goyal, Parveen Kumar
    Sangwan, Kavita
    CURRENT PHARMACOLOGY REPORTS, 2024, 10 (02) : 96 - 120
12345